LumiraDx Limited
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Veronique Ameye EMBA,
- Full Time Employees
- 1,210
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 3 More London Riverside London United Kingdom SE1 2AQ
- IPO Date
- Mar 19, 2021
- CIK
- 0001685428
- Website
- lumiradx.com
- Similar Companies
- Business
- LumiraDx Limited develops, manufactures and commercializes next-generation point-of-care diagnostic platforms and tests that deliver lab-comparable results in minutes for community-based healthcare settings worldwide. Founded in 2014 and headquartered in London, UK, the company offers its proprietary LumiraDx Platform, a portable, battery-powered, microfluidic instrument supporting assays for infectious diseases including SARS-CoV-2 antigen, SARS-CoV-2 & Flu A/B, SARS-CoV-2 & RSV; cardiovascular markers such as NT-proBNP, high-sensitivity Troponin I, D-Dimer; diabetes via HbA1c; inflammation with CRP; coagulation through INR; and pipeline products for molecular tuberculosis and additional conditions, deployed across laboratories, urgent care, physician offices, pharmacies, schools and workplaces in the US, Europe including Switzerland and Germany via distributors like Axon Lab AG, Japan, South Africa, Brazil and Colombia. In late 2023, LumiraDx enters into a definitive agreement for Roche Diagnostics to acquire its point-of-care technology platform and related entities for $295 million plus up to $55 million in funding support, with the transaction expected to close by mid-2024 and the assets integrated into Roche to expand decentralized testing globally; recent initiatives include a 2023 distribution partnership with Axon Lab AG for Switzerland and Germany, a strategic collaboration with AstraZeneca and Everton in the Community for heart and lung screening hubs in England, and a 2022 $14.2 million grant from the Bill & Melinda Gates Foundation to advance point-of-care molecular tuberculosis testing in developing countries.
AssureCKD Appoints Former LumiraDx Technical Director Dr. Aman Khan as Chief Technology Officer to Lead Diagnostic Platform Development
Former Alere and LumiraDx R&D Chief Nigel Lindner Joins CLEU Diagnostics to Launch Revolutionary LabSimple Diagnostic Platform
Why Is LumiraDx (LMDX) Stock Down 13% Today?
LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th
Roche to buy part of LumiraDx diagnostics platform for $295 million
LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
Best Penny Stocks Today? 3 To Watch Under $4 Now
Penny Stocks To Buy? 4 Under $5 To Watch Right Now
LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal
Why Is LumiraDx (LMDX) Stock Down 35% Today?
Why Is LumiraDx (LMDX) Stock Up 323% Today?
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
LumiraDx Limited (LMDX) Loses -25.54% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
What Makes LumiraDx Limited (LMDX) a New Buy Stock
LumiraDx Limited (LMDX) Q2 2023 Earnings Call Transcript
LumiraDx Limited (LMDX) Reports Q2 Loss, Misses Revenue Estimates
LumiraDx Reports Second Quarter 2023 Results
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24
LumiraDx's Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests
Why Is LumiraDx (LMDX) Stock Up 30% Today?